3. Significant Strategic Drug Collaborations - Related Parties
|6 Months Ended|
Jun. 30, 2019
|Significant Strategic Drug Collaborations - Related Parties|
|Significant Strategic Drug Collaborations - Related Parties||
The Company has entered into various research, development, license and supply agreements with Takeda Pharmaceuticals Co. Ltd., Serum Institute of India (“Serum Institute”), its controlling stockholder Pharmsynthez and SynBio LLC (“SynBio”), a wholly owned subsidiary of Pharmsynthez. The Company and its collaborative partners continue to engage in research and development activities with no resultant commercial products through June 30, 2019. No amounts were recognized as revenue related to these agreements during the three and six months ended June 30, 2019 or 2018. Subsequent to quarter end, the related party ownership interest in the Company materially changed in connection with the Offering.
The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.
Reference 1: http://www.xbrl.org/2003/role/disclosureRef